In this study, we evaluated the heterogeneous phenotypes of CD8+ T cells in ccRCC to enhance the understanding of TME and provide prognostic prediction and ICB therapeutic guidance for ccRCC patients. This evidence concerns the gene CD8A and nonpapillary renal cell carcinoma.